Resistance training and hormone replacement increase MMP-2 activity, quality and quantity of bone in ovariectomized rats

AIMS: The aim of the present study was to investigate the influence of resistance training (RT) and hormone replacement (HR) on MMP-2 activity, biomechanical and physical properties bone of ovariectomized (OVX) rats. METHODS: Sprague-Dawley female rats were grouped into six experimental groups (n = 11 per group): sham-operated sedentary (SHAM Sed), ovariectomized sedentary (OVX Sed), sham-operated resistance training (SHAM RT), ovariectomized resistance training (OVX RT), ovariectomized sedentary hormone replacement (OVX Sed-HR), and ovariectomized resistance training hormone replacement (OVX RT-HR). HR groups received implanted silastic capsules with a 5% solution of 17ß-estradiol (50 mg 17ß-estradiol/ml of sunflower oil). In a 12-week RT period (27 sessions; 4-9 climbs) the animals climbed a 1.1 m vertical ladder with weights attached to their tails. Biomechanical and physical bone analyses were performed using a universal testing machine, and MMP-2 activity analysis was done by zymography. RESULTS: Bone density and bone mineral content was higher in the RT and HR groups. The MMP-2 activity was higher in the RT and HR groups. The biomechanical analysis (stiffness, fracture load and maximum load) demonstrated better bone tissue quality in the RT associated with HR. CONCLUSION: The RT alone as well as when it is associated with HR was efficient in increasing MMP-2 activity, biomechanical and biophysical properties bone of ovariectomized rats.(AU)

Thrombolytic protein from cobra venom with anti-adhesive properties.

A metalloproteinase anticoagulant toxin of molecular weight 66 kDa has been purified from the venom of Indian monocled cobra (Naja kaouthia). This toxin named as NKV 66 cleaved fibrinogen in a dose and time dependent manner. The digestion process was specific to Aα chain and cleaved fibrinogen to peptide fragments. NKV 66 completely liquefied the fibrin clots developed in vitro in 18 h. Plasma recalcification time and thrombin time were significantly prolonged following treatment of plasma with NKV 66. NKV 66 significantly inhibited ADP and collagen induced platelet aggregation in a dose dependent manner. It showed disintegrin like activity on A549 cells cultured in vitro. About 40% inhibition of adherence of A549 cells to matrix was observed following NKV 66 treatment also NKV 66 treated A549 cells were drastically inhibited from passing through the matrix in cell invasion assays in vitro, suggesting anti-adhesive properties of NKV 66.

Inhibitory effect of arazyme on the development of atopic dermatitis-like lesions in BALB/c and Nc/Nga mice.

Arazyme is a metalloprotease released by Aranicola proteolyticus that was shown to inhibit cytokine release in HaCaT and endothelial cells. However, the regulatory effects of arazyme in atopic dermatitis remain to be fully understood. In the present study, the anti­inflammatory effects of arazyme in BALB/c and Nc/Nga mice induced with 2,4­dinitrochlrobenzene (DNCB) were investigated. BALB/c mice were sensitized with DNCB and were subsequently administered arazyme for 4 weeks either orally, dorsally or orally/dorsally. Arazyme administration significantly reduced epidermal thickening and infiltration of inflammatory cells into the dermis compared with the DNCB group. However, serum immunoglobulin E (IgE) levels were not altered by arazyme treatment. Additionally, the level of secretion of interleukins (IL)­4, ­5 and ­13 in the splenocytes of BALB/c mice was elevated following stimulation with concanavalin A, while the increase of IL­4 and IL­13 was inhibited by arazyme. Administration of arazyme (25 mg/kg in phosphate­buffered saline) to Nc/Nga mice that had been sensitized with DNCB for 6 weeks reduced the skin severity score compared with that in the DNCB group and inhibited the histological manifestations of atopic dermatitis­like skin lesions. In addition, the serum IgE levels were reduced in the arazyme­treated NC/Nga mice relative to the DNCB group. Collectively, these results indicated that arazyme attenuates the development of atopic dermatitis­like lesions via lowering the levels of IgE and inflammatory cytokines. The results of the present study will aid in the development of effective therapeutic strategies for the treatment of allergic diseases, including atopic dermatitis.

Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.

Diarrhea and amebic liver abscesses due to invasive Entamoeba histolytica infections are an important cause of morbidity and mortality in the developing world. Entamoeba histolytica adherence and cell migration, two phenotypes linked to virulence, are both aberrant in trophozoites deficient in the metallosurface protease EhMSP-1, which is a homologue of the Leishmania vaccine candidate leishmanolysin (GP63). We examined the potential of EhMSP-1 for use as a vaccine antigen to protect against amebic liver abscesses. First, existing serum samples from South Africans naturally infected with E. histolytica were examined by enzyme-linked immunosorbent assay (ELISA) for the presence of EhMSP-1-specific IgG. Nine of 12 (75%) people with anti-E. histolytica IgG also had EhMSP-1-specific IgG antibodies. We next used a hamster model of amebic liver abscess to determine the effect of immunization with a mixture of four recombinant EhMSP-1 protein fragments. EhMSP-1 immunization stimulated a robust IgG antibody response. Furthermore, EhMSP-1 immunization of hamsters reduced development of severe amebic liver abscesses following intrahepatic injection of E. histolytica by a combined rate of 68% in two independent animal experiments. Purified IgG from immunized compared to control animals bound to the surface of E. histolytica trophozoites and accelerated amebic lysis via activation of the classical complement cascade. We concluded that EhMSP-1 is a promising antigen that warrants further study to determine its full potential as a target for therapy and/or prevention of invasive amebiasis.

Biochemical properties of a new PI SVMP from Bothrops pauloensis: inhibition of cell adhesion and angiogenesis.

In the present work, we demonstrate some biochemical and functional properties of a new PI snake venom metalloproteinase (SVMP) isolated from Bothrops pauloensis snake venom (BpMP-II), in addition we evaluated its capacity to inhibit endothelial cell adhesion and in vitro angiogenesis. BpMP-II was purified after a combination of three chromatography steps and showed molecular mass of 23,000 Da determined by MALDI-TOF, an isoelectric point of 6.1 and the sequence of some fragments obtained by MS/MS (MALDI TOF\TOF) presented high structural similarity with other PI-SVMPs. BpMP-II showed proteolytic activity against azocasein, was able to degrade bovine fibrinogen and was inhibited by EDTA, 1.10 phenantroline and ß-mercaptoethanol. BpMP-II did not induce local hemorrhage in the dorsal region of mice even at high doses and did not affect plasma creatine kinase (CK) levels when administered intramuscularly into the gastrocnemius muscle of mice. Moreover, this metalloproteinase decreased tEnd cells viability at concentrations higher than 20 µg/mL. With sub-toxic doses this metalloproteinase affected tEnd cell adhesion and was also able to inhibit in vitro angiogenesis. BpMP-II showed very important functional properties suggesting considerable therapeutic potential for this class of protein.

Expressão gênica funcional das metalotioneínas no carcinoma epidermóide bucal / Functional gene expression of metallothioneins in oral squamous cell carcinoma

O carcinoma epidermoide bucal (CEB) é uma malignidade epitelial que causa grande mortalidade. As metalotioneínas (MTs) são proteínas envolvidas na homeostasia de metais e eventos oxidativos. Estudos de expressão proteica a apontaram como marcadora de prognóstico e comportamento metastático para o CEB. A análise da expressão gênica das mesmas tem auxiliado no entendimento deste papel para outros tumores, mas ainda não foi estudada no CEB. O objetivo deste trabalho foi avaliar o perfil de expressão gênica das MTs no CEB e em fragmentos de mucosa oral (MOC), além de sua relação com dados clínicopatológicos, comportamento metastático e prognóstico. Para tal, foram utilizadas amostras armazenadas a -80º C no Banco Nacional de Tumores do Instituto Nacional de Câncer, constando de 35 casos de CEB de língua e/ou assoalho bucal e 35 MOC. Todos os fragmentos foram submetidos ao qRT-PCR com uso de TaqMan® para os genes: MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1X, MT2A, MT3 e MT4. A expressão dos genes MT1B e MT1H foi raramente detectada. Houve queda significativa de expressão dos genes MT1A, MT1X, MT3 e MT4 e aumento significativo de expressão de MT1F no CEB com relação à MOC. Casos de baixa expressão de MT1G tiveram pior prognóstico. A alta expressão de MT1X indicou casos não metastáticos e a alta expressão de MT3 indicou casos metastáticos. Em suma, foi demonstrado pela primeira vez o perfil gênico das MTs no CEB, indicando que a mesma pode fornecer informações sobre o prognóstico e comportamento metastático do CEB...

The oral squamous cell carcinoma (OSCC) is a malignancy that causes high mortality. Metallothioneins (MTs) are proteins involved in metal homeostasis and antioxidant events. Studies regarding its protein expression indicated its potential as marker of prognosis and metastatic behavior, also for OSCC. The analysis of its specific gene expression can clarify its importance in these aspects and no study has been done for OSCC. The aim of this work was to evaluate the profile of gene expression of MTs in OSCC and samples of non-neoplastic oral mucosa (OM), evaluating its relationship with clinic-pathologic characteristic, metastatic behavior and prognosis for OSCC. For this, tissue samples archived at -80º C at the National Bank of Tumors of the Brazilian National Institute of Cancer were collected, in a total of 35 cases of OSCC and 35 fragments of OM. All tissues were submitted to qRTPCR with TaqMan® for the genes: MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1X, MT2A, MT3 e MT4, besides the constitutive gene GAPDH. Expressions of MT1B and MT1H were rarely detected. There was significant loss of expression for MT1A, MT1X, MT3 and MT4 and gain of expression for MT1F comparing OSCC with OM. Cases with down-regulation of MT1G had the worst prognosis. Up-regulation of MT1X indicated non-metastatic cases whereas up-regulation of MT3 indicated metastatic ones. In conclusion, this study shows for the first time the profile of gene expression of MTs on OSCC indicating distinctive patterns of regulation for each, and giving associations with prognosis and metastatic behavior of cases...

Peripheral delivery of a CNS targeted, metalo-protease reduces aß toxicity in a mouse model of Alzheimer's disease.

Alzheimer's disease (AD), an incurable, progressive neurodegenerative disorder, is the most common form of dementia. Therapeutic options have been elusive due to the inability to deliver proteins across the blood-brain barrier (BBB). In order to improve the therapeutic potential for AD, we utilized a promising new approach for delivery of proteins across the BBB. We generated a lentivirus vector expressing the amyloid ß-degrading enzyme, neprilysin, fused to the ApoB transport domain and delivered this by intra-peritoneal injection to amyloid protein precursor (APP) transgenic model of AD. Treated mice had reduced levels of Aß, reduced plaques and increased synaptic density in the CNS. Furthermore, mice treated with the neprilysin targeting the CNS had a reversal of memory deficits. Thus, the addition of the ApoB transport domain to the secreted neprilysin generated a non-invasive therapeutic approach that may be a potential treatment in patients with AD.

Análise de metaloproteases de matriz extracelular como indicador prognóstico nos gliomas malignos / Analysis of matrix metalloproteinase as prognostic indicator in malignant gliomas

Introdução: Metaloproteases de matriz extracelular(MMP) são enzimas proteolíticas sintetizadas na fase de fenótipo mais agressivo dos gliomas malignos, degradando proteínas da matriz extracelular,ocasionando ruptura da barreira hematoencefálica e contribuindo para a resposta neuroinflamatória,angiogênese e migração.Estudos mostram expressão de gelatinase A(MMP-2)proeminentemente nas células gliais tumorais,com pouca expressão na microvasculatura,enquanto expressão de gelatinase B(MMP-9)é proeminente na microvasculatrua, com porco sinal nas células tumorais.Objetivo:Neste estudo analisamos amostras de soro de 34 pacientes com gliomas malignos recidivos,antes e durante o tratamento com álcool perílico por via inalatória para determinar se a expressão de MMP poderia ser usada como indicador prognóstico.Métodos:A atividade gelatinade (MMP-2, MMP-9)nas amostras de soro foi determinada por zimografia e a atividade enzimática relativa foi determinada utilizando-se programa de análise densitométrica.Os valores foram correlacionados com exames de imagem e sobrevida dos pacientes. Resultados:Os resultados obtidos em nosso estudo evidenciaram que os pacientes com gliomas malignos apresentaram aumento da expressão de MMP-2 e MMP-9 quando comparados com pacientes saudáveis.Expressão aumentada de MMP-2 foi proporcional à progressão tumoral,sobrevida desfavorável e área de edema peritumoral.Conclusão:Esses resultados indicam proporcionalidade entre a expressão de MMP-2 e a malignidade dos gliomas, sugerindo seu emprego como indicador prognóstico para recorrência tumoral pós-operatória e sobrevida desfavorável dos pacientes.

Ammodytase, a metalloprotease from Vipera ammodytes ammodytes venom, possesses strong fibrinolytic activity.

Ammodytase, a high molecular mass metalloproteinase with fibrinogenolytic and fibrinolytic activities, was purified from long-nosed viper (Vipera ammodytes ammodytes) venom by gel filtration, affinity and ion-exchange chromatographies. The enzyme is a single-chain glycoprotein with apparent molecular mass of 70 kDa and isoelectric point of 6.6. Ammodytase shows very weak hemorrhagic activity, and only at doses higher than 20 microg. Consistent with this, it partially degrades some components of the extracellular matrix in vitro. It cleaves the Aalpha-chain of fibrinogen preferentially at peptide bonds Glu(441)-Leu(442) and Glu(539)-Phe(540). Its preference for bulky and hydrophobic amino acids at the P1' position in substrates is demonstrated by its hydrolysis of only the Gln(4)-His(5) and Tyr(16)-Leu(17) bonds in the B-chain of insulin. Ammodytase is able to dissolve fibrin clots. It neither activates nor degrades plasminogen and prothrombin, and has no effect on collagen- or ADP-induced platelet aggregation in vitro. LC/MS and MS/MS analyses of its tryptic fragments demonstrated that ammodytase is a P-III class snake venom metalloproteinase composed of metalloproteinase, disintegrin-like and cysteine-rich domains. Its similarity to hemorrhagins from V. a. ammodytes venom, accompanied by very low toxicity, makes ammodytase a promising candidate as an antigen to prepare antisera against these most dangerous components of the viper's venom. Moreover, its ability to degrade fibrin clots suggests its clinical use as an antithrombotic agent.

Metaloproteinasas y cáncer vesical: estado actual / Metaloproteinases and bladder cancer: state of the art

Durante los últimos diez años el papel de las metaloproteinasas en el desarrollo tumoral haalcanzado una importante relevancia. El descubrimiento de nuevas metaloproteinasas ha demostrado, no sólo su implicación en la disrupción de la matriz extracellular y la consecuente diseminación tumoral sino que diversos estudios han desvelado su papel en procesos deiniciación, promoción tumoral y apoptosis.Recientes trabajos desvelan también la relación entre niveles elevados de ciertas metaloproteinasas y sus inhibidores, sobre todo MMP2, MMP9, 17MPl Y 17MP2 en tejidoparafinado, orina y suero de pacientes con carcinoma vesical con características clínicopatológicasdesfavorables en cuanto a estadio y grado, por lo que en un futuro podríanconvertirse en buenas predictoras del comportamiento del cáncer vesical

No disponible

Functional roles of the two distinct domains of halysase, a snake venom metalloprotease, to inhibit human platelet aggregation.

Halysase, a hemorrhagic metalloprotease, has an apparent molecular weight of 66kDa and belongs to the class P-III snake venom metalloprotease. Class P-III snake venom metalloproteases have multifunctional domains including a protease domain and a disintegrin-like domain. Halysase was able to preferentially hydrolyze the alpha-chain of fibrinogen. Proteolytic activity of the enzyme was completely inhibited by metal chelating agents but not by other typical protease inhibitors. The enzyme principally cleaves X-Leu, X-Tyr, X-Phe, and X-Ala peptide bonds of the oxidized insulin B-chain. Halysase strongly suppresses collagen-induced human platelet aggregation in a dose-dependent manner. Apohalysase that is devoid of its metalloprotease activity was also able to inhibit the platelet aggregation to a certain extent. Experimental evidence clearly indicates that each of the two distinct domains of halysase, the metalloprotease and the disintegrin-like domains, plays its characteristic role to inhibit human platelet aggregation.

Metaloproteinasas y piel / Metalloproteinases and the skin

Las metaloproteinasas son endopeptidasas que desarrollan una función degradativa, generalmente dirigida a la matriz extracelular. Están relacionadas estructuralmente y se clasifican según su especificidad de sustrato y su estructura primaria. Su denominación se efectúa siguiendo una numeración correlativa según su fecha de descripción, pero existen para ellas nombres alternativos que hacen referencia generalmente al sustrato al que se dirigen o a su ubicación. El análisis de la estructura primaria de estas enzimas permite identificar los llamados dominios estructurales. Todos los miembros de las metaloproteinasas contienen un péptido señal, un propéptido y un dominio catalítico aminoterminal que contiene el sitio fijador de cinc. En la piel existen una serie de circunstancias tanto fisiológicas como patológicas en las que se evidencia un aumento de producción de metaloproteinasas. Ocurre en la reparación de heridas, en el envejecimiento cutáneo, en las enfermedades am (AU)